HSHHSH Health Technology Supplier Hub
Home › Suppliers › Cegedim › Risk

Cegedim: risk summary

Summaries are drawn from public sources and link to them. HSH does not give a risk rating: read the summary and sources and reach your own view. Unproven allegations are labelled as such. Suppliers can submit a response, which is shown alongside.

Financial

Latest full-year results from official filings.

FY2025 revenue €649.2m (-0.8%); operating margin 4.7%; net income €9.4m.

Balance sheet figures not captured from release.

Researched 8 Nov 2026

Adverse media

Credible news about incidents, disputes, legal action or restructuring in the last 24 months.

Dec 2024: Cegedim's UK GP software subsidiary INPS (Vision) entered administration citing financial difficulties; Cegedim Rx said its pharmacy business was unaffected. In Aug 2025 OneAdvanced bought the Vision EPR assets.

Researched 10 Nov 2026

Cyber & information governance

Data breaches, cyber incidents, regulator action and assurance status.

Feb 2026: France's health ministry disclosed a late-2025 cyberattack on Cegedim Santé doctor accounts exposing data of up to 15 million patients, including sensitive notes for about 164,000. Feb 2026: France's top court upheld a 2024 CNIL fine of EUR 800,000. NHS DSPT status not yet checked.

Researched 10 Nov 2026

Regulatory & clinical safety

Recalls, safety notices, regulator action and clinical safety concerns.

No recalls, safety notices or clinical safety incidents involving Cegedim products found in HSH's search of the last 24 months.

Researched 10 Nov 2026